to detect prostate cancer (PCa) due to targeting error, inadequate sampling, or did the radiologist overcall the MRI lesion as positive? This perplexing situation leads to clinical uncertainty as to whether repeating another MR/US fusion biopsy session would be beneficial. In this study, we sought to determine whether ConfirmMDxÒ, a validated DNA methylation field effect assay, would be clinically useful if applied to TB þ SB cores with benign pathology.
INTRODUCTION AND OBJECTIVES:
With infection rates and quinolone resistance increasing, we require straightforward alternatives to transrectal biopsy. TP biopsy has historically been more expensive to deliver and dependent on GA and operating theatre facilities. We investigated the use of a TP access system, Precision Point, under LA in the outpatient setting, and assessed sampling of the prostate and tolerability.
METHODS: Case selection: Patients with TRUSBx histological discordance, active surveillance and cancer screening.
ANTIBIOTICS: Patients received pre-procedure antibiotics in accordance with local hospital guidelines.
EQUIPMENT: PrecisionPointä transperineal access system. Triplane or biplane transrectal ultrasound transducer in biplane mode.
LA TECHNIQUE: Subcutaneous perineal nerve block þ prostatic apex block þ periprostatic nerve block (PPNB). No sedation.
BIOPSY PROTOCOL: Free hand transperineal biopsy using Ginsburg protocol AE Cognitive MRI supported targeted biopsies.
DATA: Prospectively collected. RESULTS: Characteristics: 116 patients underwent LATP Biopsy from 4 institutions. 21 (18%) were performed for active surveillance and cancer was detected in 15 (71.4%) patients. 69 (59%) were performed for cancer screening. 26 (22.4%)were re-classification biopsies.
Median age was 65.5(48-79)years, median PSA 7.5 (2.6-43)ng/ ml; median prostate volume 121.6(24-217)cc. and median number of biopsies was 24 (16-32).
Complications: There was no urinary retention or procedures abandoned due to pain. 3 patients experienced vaso-vagal episodes. 1 patient developed haematoma. 1 patient developed epididymo-orchitis within 2 weeks and was the only re-admission.
Oncologic outcomes: Prostate cancer was found in 72/116 (62%) patients of which 57 (49%) had clinically significant prostate cancer.
Patient reported outcomes: 4 out of 34 men (11.8%) said a repeat biopsy would be a significant problem. 11 out of 34 (32.4%) said it would be no problem at all.
CONCLUSIONS: LATP biopsy using a Transperineal Access System is safe and well tolerated. The procedure is more flexible and efficient than traditional stepper systems. We encourage other centres to adopt this technique. We also anticipate use of MRIeUS fusion using this technique in the outpatient setting.
Source of Funding: none

MP24-17 CAN WE BETTER UNDERSTAND PI-RADS 3 LESIONS AND AVOID UNNECESSARY BIOPSIES?
INTRODUCTION AND OBJECTIVES: PI-RADS 3 lesions by definition, are equivocal lesions on multi-parametric MRI with a lower likelihood for detection of clinically significant prostate cancer. We aim to assess for clinical characteristics that might aid in discriminating clinically significant prostate cancer (csPCa) in men with PI-RADS (version 2) 3 lesions.
METHODS: Multicenter (Weill Cornell Medicine, UCLA and Stanford) study of biopsy naive men (n [ 211) who underwent MRItargeted and systematic biopsies for PI-RADS 3 using Artemis (Eigen, Grass Valley, CA). Clinical parameters analyzed included age, PSA level prior to biopsy, prostate volume and PSA density (PSAD). Men with Grade Group ! 2 on either target or template cores were considered harboring csPCa. Chi-squared tests and independent two-sample t-tests compared groups and receiver operating characteristic (ROC) curves explored the prognostic ability of continuous parameters. Multivariable logistic regression assessed for parameters independently associated with csPCa.
RESULTS: The mean age of the cohort was 63.4 years. Of the 211 men that underwent targeted biopsy, 52 (24.6%) had csPCa. Patients with csPCa had similar PSA levels (mean 6.99 vs. 6.11 ng/ml, p [ 0.42) to those without csPCa. However, men with csPCa had lower prostate volume (mean 40 vs 56 ml, p < 0.001) and higher PSA density (0.2 vs. 0.12, p [ 0.03). From ROC analyses, prostate volume demonstrated the largest AUC compared with PSA and prostate density (0.73 [95% CI 0.65-0.81] vs. 0.51 and 0.64, respectively). Youden's J statistic statistic determined 37.35 ml as an optimal cutoff for prostate volume (sensitivity 63%, specificity 82%). Multivariable modeling revealed older age and smaller prostate volume were independently associated with Grade Group ! 2 disease (Table) .
CONCLUSIONS: We found biopsy naive older men with lower prostate volumes more likely to have csPCA with PI-RADS 3 lesions. However, the clinical application of prostate volume as a decision aid is limited by its sensitivity. Our findings demonstrate an opportunity
